Grŵp Strategaeth Meddyginiaethau Cymru Gyfan
All Wales Medicines Strategy Group

Final Appraisal Recommendation

Advice No: 1020 – September 2020

Doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo®) 100mg/300mg/245mg film-coated tablets

Submission by Merck Sharp & Dohme Ltd

Recommendation of AWMSG

Doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo®) is recommended as an option for use within NHS Wales for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, lamivudine, or tenofovir.

This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.

Additional note(s):

- Please refer to the Summary of Product Characteristics section 4.4 (special warnings and precautions for use) and 5.1 (pharmacodynamic properties) for further information, as specified in the licenced indication

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3648), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.